Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Insulet to Announce Third Quarter 2022 Financial Results on November 3, 2022
ACTON, Mass. --(BUSINESS WIRE)--Sep. 22, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced plans to release its financial results for the third quarter of 2022 on November
View HTML
Toggle Summary Insulet Announces CE Mark Approval for Omnipod® 5 Automated Insulin Delivery System
ACTON, Mass. --(BUSINESS WIRE)--Sep. 20, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced it has received CE marking under the European Medical Device Regulation for its
View HTML
Toggle Summary Insulet Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 Diabetes
Omnipod 5 is the first tubeless AID System cleared in the U.S. for preschool children ACTON, Mass. --(BUSINESS WIRE)--Aug. 22, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today
View HTML
Toggle Summary Insulet to Present at Upcoming Investor Conferences
ACTON, Mass. --(BUSINESS WIRE)--Aug. 5, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at four upcoming investor conferences (all Eastern Time): The
View HTML
Toggle Summary Insulet Reports Second Quarter 2022 Revenue Increase of 14% Year-Over-Year (18% Constant Currency¹)
Recently Launched U.S. Full Market Release for Omnipod ® 5 - Now Available through Retail Pharmacies ACTON, Mass. --(BUSINESS WIRE)--Aug. 4, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of
View HTML
Toggle Summary Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery System
Omnipod 5 is Now Fully Available through Retail Pharmacy Channels ACTON, Mass. --(BUSINESS WIRE)--Aug. 1, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its Omnipod ® 5
View HTML
Toggle Summary Insulet to Announce Second Quarter 2022 Financial Results on August 4, 2022
ACTON, Mass. --(BUSINESS WIRE)--Jun. 30, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced plans to release its financial results for the second quarter of 2022 on August
View HTML
Toggle Summary Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years
Insulet Presents Pivotal Extension Data for Preschool Children and Other Omnipod® 5 System Clinical Research at American Diabetes Association 82 nd Scientific Sessions ACTON, Mass. --(BUSINESS WIRE)--Jun. 3, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in
View HTML
Toggle Summary Insulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference
ACTON, Mass. --(BUSINESS WIRE)--Jun. 2, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at the William Blair & Company 42 nd Annual Growth Stock Conference
View HTML
Toggle Summary Insulet Hosts Groundbreaking Ceremony for its New Manufacturing Facility in Malaysia
ACTON, Mass. --(BUSINESS WIRE)--Jun. 1, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host a groundbreaking ceremony for its new manufacturing facility in Malaysia , further
View HTML
Toggle Summary Insulet Announces CEO Transition
Director Jim Hollingshead to Succeed Shacey Petrovic as President and CEO, Effective June 1, 2022 Petrovic and Hollingshead to Continue as Members of Insulet’s Board of Directors ACTON, Mass. --(BUSINESS WIRE)--May 5, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global
View HTML
Toggle Summary Insulet Reports First Quarter 2022 Revenue Increase of 17% Year-Over-Year
ACTON, Mass. --(BUSINESS WIRE)--May 5, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for the three months ended March 31, 2022 .
View HTML
Toggle Summary Insulet’s 2021 Sustainability Report Reveals Progress on Strategy to Deliver Growth with Purpose
ACTON, Mass. --(BUSINESS WIRE)--May 2, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the release of its 2021 Sustainability Report.
View HTML
Toggle Summary Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes
ACTON, Mass. --(BUSINESS WIRE)--Apr. 27, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented new Omnipod® 5 Automated Insulin Delivery (AID) System study results in type 2
View HTML
Toggle Summary Insulet to Announce First Quarter 2022 Financial Results on May 5, 2022
ACTON, Mass. --(BUSINESS WIRE)--Apr. 7, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced plans to release its financial results for the first quarter of 2022 on May 5,
View HTML